Follow-Up Evaluation in Multiple Sclerosis
All patients with MS require annual brain MRI monitoring at minimum, with T2 FLAIR and gadolinium-enhanced T1-weighted sequences to detect new or enlarging lesions and assess disease activity, while patients on high-risk therapies need MRI every 3-4 months. 1
MRI Monitoring Protocol
Standard Follow-Up Imaging
Required MRI sequences:
- T2 FLAIR and T2-weighted sequences to detect new/enlarging lesions
- Gadolinium-enhanced T1-weighted sequences to identify active inflammatory lesions (minimum 5-minute delay post-contrast)
- Diffusion-weighted imaging for patients at risk of progressive multifocal leukoencephalopathy (PML)
- Technical specifications: ≥1.5T field strength, slice thickness ≤3mm, in-plane resolution 1×1mm 1
Risk-Stratified MRI Frequency
High-risk patients requiring MRI every 3-4 months:
- Natalizumab-treated patients who are JCV seropositive with ≥18 months treatment duration
- Patients switching from natalizumab to other disease-modifying drugs (fingolimod, alemtuzumab, dimethyl fumarate) for up to 12 months post-switch
- Any patient on therapies with opportunistic infection risk 1
Standard-risk patients requiring annual MRI:
- JCV seronegative patients on natalizumab
- Patients on other disease-modifying therapies with stable disease 1
Important caveat: Spinal cord imaging is not routinely necessary for follow-up, unlike at diagnosis 1. The evidence shows that after 2 years of stable treatment with highly effective therapies like ocrelizumab, MRI intervals can potentially be extended as the number needed to scan increases substantially (reaching 81.3 at 30 months and 152.9 at 36 months) 2.
Treatment Response Monitoring
Perform reference MRI at 6 months after treatment initiation to establish a new baseline once the drug has taken effect, then compare with a scan at 12 months to assess treatment efficacy 1. New T2 lesions on these comparative scans indicate inadequate treatment response, though this requires high-quality comparable scans interpreted by trained readers 1.
When switching therapies: Obtain MRI at the time of discontinuation and after starting the new treatment to detect both resurgent disease activity and carry-over opportunistic infections 1.
Clinical Assessment Components
Disability Measurement
- Expanded Disability Status Scale (EDSS) remains the standard but has limitations in sensitivity
- Multiple Sclerosis Functional Composite (MSFC) provides more sensitive detection of change over time, particularly:
- Timed 25-Foot Walk Test (T25FWT) - correlates strongly with EDSS and lesion volume
- 9-Hole Peg Test (9HPT) for upper extremity function
- Paced Auditory Serial Addition Test (PASAT) for cognitive processing 3
Cognitive Evaluation
Perform baseline cognitive assessment and re-baseline at approximately 1 year to control for practice effects and measurement bias, as nearly 40% of patients classified as cognitively impaired at baseline revert to cognitively preserved status at re-baseline 4. Use the Brief International Cognitive Assessment for MS (BICAMS) battery, which includes:
- Symbol Digit Modalities Test (SDMT) - most sensitive to MS-related cognitive changes
- California Verbal Learning Test-II (CVLT-II)
- Brief Visuospatial Memory Test-Revised (BVMT-R) 5, 6
Cognitively preserved patients remain stable with conversion rates to impairment below 1%, so they can be monitored less frequently, while those with confirmed impairment at re-baseline require ongoing monitoring 4.
Safety Surveillance
Screen specifically for:
- PML warning signs: New or atypical lesions on FLAIR, T2, and diffusion-weighted imaging, particularly in patients on natalizumab, alemtuzumab, rituximab, or dimethyl fumarate 1
- Unexpected disease activity including paradoxical reactions during therapy switches
- Comorbidities that may affect treatment decisions or outcomes 1
Disease Progression Markers
While brain volume measurements and spinal cord atrophy predict disability, these are difficult to obtain and interpret in routine practice and are not yet recommended for standard clinical use 1, 7. However, automated lesion quantification software (such as LesionQuant) can supplement neuroradiologist evaluation by providing objective lesion counts and detecting early atrophy that may be missed on visual inspection 8.
Common pitfall: Do not rely solely on EDSS for monitoring, as it underdetects cognitive changes and subtle functional decline. The MSFC captures aspects of neurological function not measured by EDSS and is more sensitive to therapeutic effects 3.